RecallDepth
Class III Terminated

AMITIZA (lubiprostone) capsules 8 mcg. 60-count bottle, Rx Only. Marketed by: Sucampo Pharma Americas, LLC, Rockville MD 20850 and Takeda Pharmaceuticals America, Inc. Deerfield, IL 60015. Active Ingredient made in Japan, encapsulated in the United States. NDC 64764-080-60

Company
Takeda Development Center Americas, Inc.
Recall Initiated
November 6, 2018
Posted
November 21, 2018
Recall Number
D-0286-2019
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
69,075 60-count bottles (4,144,500 capsules)
Firm Location
Deerfield, IL, United States

Reason for Recall

Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.

Distribution

Product was distributed to 32 distributors throughout the United States.

Lot / Code Info

Lot # 3098628-61, exp. date 02/28/2021

More recalls by Takeda Development Center Americas, Inc.

View all recalls by this company →

Other recent Class III Drug recalls